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Abstract
Context—Use of both conventional medicines and herbs/natural products are increasing in the 
United States (US). Consequently, individuals are more likely to be exposed to potentially harmful 
interactions between these products.
Objective—To examine the use of both herbs/natural products and conventional medications in a 
rural community; examine the prevalence of potential interactions between herbs/natural products 
and conventional medications; and identify factors associated with exposure to such interactions.
Design—Population-based epidemiological study.
Setting—Data for this paper were collected between 1999 and 2004 as part of the Johnston 
County Osteoarthritis Project.
Participants—Limited to civilian, non-institutionalized, Caucasian and African American 
residents, age 45 years or older, of Johnston County, North Carolina. Data used in this paper are 
from 2,523 individuals who completed face-to-face interviews.
Main Outcome Measures—Prevalence of herb/natural product use and exposure to potential 
interactions between these products and conventional medications.
Address correspondence to Dr. Susan J. Blalock, Division of Pharmaceutical Outcomes and Policy, School of Pharmacy, CB# 7360, 
University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599-7360. s_blalock@unc.edu. Telephone: 919-962-0080 (work), 
919-933-5683 (home). Fax: 919-966-8486. 
HHS Public Access
Author manuscript
Altern Ther Health Med. Author manuscript; available in PMC 2017 June 12.
Published in final edited form as:













Results—Nineteen percent (n=488) of participants used at least one herb/natural product. 
Among those who used both conventional medications and herbs/natural products, more than 1 in 
5 (97 [21.9%]) were using a combination of products associated with a potential interaction. Odds 
of exposure to a potential interaction was lower among people who had health insurance and 
increased with the number of products used.
Conclusions—Many people are exposed to potential interactions between herbs/natural 
products and conventional medications. Research is needed to better understand the effect such 
interactions may have on patient care.
Introduction
Use of herbs and natural products has increased dramatically over the past 20 years in the 
United States. In a nationally representative telephone survey conducted in 1991, 2.5% of 
respondents reported having used an herb within the past year, compared to 12.1% of 
respondents in a parallel survey conducted in 1997.(1) This reflects a nearly 5-fold increase 
in herb use over a 6-year period. Data from the 2007 National Health Interview Survey 
confirms this increase in herb use with 17.7% of respondents reporting having used a 
nonvitamin, nonmineral, natural product within the past 30 days.(2) Similarly, in data 
collected between 1998 and 2004 as part of the Slone Survey, 17% of respondents reported 
using an herb or natural product within the past week.(3)
During this same time period, the use of prescription medications has continued to grow. 
Between 1997 and 2004, expenditures for outpatient prescription medications in the United 
States increased from $72.3 billion to $191.0 billion.(4) Data from the National Health and 
Nutrition Examination Survey (NHANES) indicate that, among all Americans, reported use 
of at least one prescription medication during the previous month increased from 39.1% in 
the period from 1988-1994 to 46.7% in the period from 2001-2004.(5) Use of multiple 
medications has also increased. During the period from 2001-2004, 20.2% of all Americans 
reported having used three or more prescription medications during the past month, 
compared to 11.8% who reporting doing so in the period from 1988-1994.(5) Moreover, 
medication utilization increased with age. During the period from 2001-2004, 59.6% of 
individuals age 65 and older reported using three or more prescription medications in the 
past month.
As the use of herbs/natural products and prescription medications increases, the likelihood 
that individuals may be exposed to potentially harmful interactions between these products 
increases as well. In a recent study focused on older adults (median age 75), Elmer and 
colleagues found that 5.8% were taking a combination of herbs/natural products and 
prescription medications considered to pose a significant risk for adverse events. (6) An 
additional 13.2% of participants were taking a combination of products associated with a 
theoretical or uncertain risk of adverse events. Others have observed even higher rates of 
potential interactions.(7)
Although many studies have examined factors associated with the use of herbs/natural 
products, only a few have examined the prevalence of interactions between these products 
and conventional medications.(6, 7) Moreover, we are not aware of any studies that have 
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attempted to identify factors associated with exposure to such interactions. Thus, in this 
paper, we report findings on the use of both herbs/natural products and conventional 
medications (prescription and over-the-counter) in a rural, Southern community. We also 
examine the prevalence of potential interactions among these products and identify factors 
associated with exposure to such interactions.
Methods
Study Design and Participants
Data were collected between 1999 and 2004 as part of an ongoing, federally-funded, 
population-based epidemiological study called the Johnston County Osteoarthritis Project. 
To be eligible, individuals had to be: civilian, non-institutionalized, Caucasian or African 
American, age 45 years or older, a resident of one of six selected townships in a rural county 
in the southeastern United States, and physically and mentally capable of completing study 
procedures. African Americans were purposively oversampled.
Two cohorts were recruited as part of the Johnston County project. The original cohort was 
recruited using population-based random sampling methods from 1991-1997. A second 
cohort was recruited in 2003-2004 to enrich the sample for African Americans and younger 
individuals who were deliberately targeted for inclusion. A detailed description of the 
sampling design and study protocol has been published previously.(10) Data used in this 
paper are from follow-up interviews of 1,571 individuals from the original cohort and initial 
interviews involving 952 individuals from the second cohort. The study was approved by the 
Institutional Review Boards of the School of Medicine at the University of North Carolina at 
Chapel Hill and the Centers for Disease Control and Prevention.
Data Collection Methods
All data were collected via face-to-face interviews. Most interviews were conducted in 
participants' homes. Before beginning the interview, interviewers described the study to 
participants, answered participant questions about the study, and obtained written informed 
consent to participate. Interviews were conducted with the aid of a laptop computer that 
contained all instructions and questionnaires. All questionnaires were administered orally. 
Each interview lasted an average of 90 minutes.
Measures
Utilization of Herbs and Natural Products—To assess the utilization of herbs and 
natural products, participants were read a list of 51 products and, for each product, asked to 
indicate whether or not they had used the product within the previous year. The list included 
herbs and botanical products (e.g., garlic, aloe vera), natural products obtained from animal 
sources (e.g., cod liver oil), natural hormones (e.g., phytoestrogen pills), and foods that are 
sometimes consumed for medicinal purposes (e.g., raisins soaked in gin or vodka). A 
complete list of the products assessed is included in the Appendix. Participants were also 
asked if they used any products other than those listed and, if so, to specify the products 
used. This information was used to create two variables, (1) a dichotomous variable 
indicating whether any herbs or natural products were used during the past year (0=No, 
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1=Yes) and (2) a continuous variable indicating the number of different herbs and natural 
products used. (Although use of vitamins (e.g., multivitamins, Vitamin C) and mineral 
products (e.g., calcium, zinc) was also assessed, vitamins and minerals were not included in 
variables assessing herb and natural product use.)
Utilization of Prescription and Over-the-Counter Medications—Participants were 
asked to retrieve all of the prescription and over-the-counter (OTC) medications that they 
were currently using. Medications used on either a regular or an as needed (PRN) basis were 
included. The interviewer reviewed the medications with each participant and recorded the 
name and strength for each medication. For the analyses reported in this paper, information 
concerning prescription and OTC medications was separated and a total of four variables 
were created. First, two dichotomous variables were created indicating whether the 
participant used any (1) prescription or (2) OTC medications. Second, two continuous 
variable were created to capture the number of different (1) prescription and (2) OTC 
medications used.
Potential Medication-Herb/Natural Product Interactions—Potential interactions 
between conventional medications and herbs/natural products used by study participants 
were determined by collecting and evaluating interaction data from three sources: Natural 
Medicines Comprehensive Database (online; professional version)(11), Office of Dietary 
Supplements website(12), and the National Center for Complementary and Natural 
Medicine.(13) Interactions were included if supporting data included clinical trials, 
pharmacokinetic studies, or documented case reports involving a specific drug or class of 
drug. The potential severity associated with each type of interaction was noted using the 
ratings included in the Natural Medicines Comprehensive Database.(11) Four levels of 
severity are indicated in the database: (1) insignificant (drug levels may be affected, but a 
clinically significant interaction is not likely); (2) mild (mild impairment or mild discomfort 
possible); (3) moderate (moderate impairment or significant discomfort possible), and (4) 
high (life threatening or severe impairment possible). Potential interactions were excluded if 
supporting data were based only on in vitro or animal model research. Theoretical 
interactions were also excluded.
Health Insurance Status—Insurance status was coded as a dichotomous variable (0=No 
insurance or Medicare Part A only, 1=Insurance other than or in addition to Medicare Part 
A). This dichotomous coding was used because individuals with no insurance or only 
Medicare Part A have no coverage for outpatient services.
Health Status—Four health status indicators were assessed: disability, depressive 
symptoms, fatigue, and comorbidities. Disability was assessed using the 20-item Health 
Assessment Questionnaire (HAQ).(14) Participants rate the degree of difficulty they 
experience performing different activities of daily living using a 4-point scale ranging from 
0=Able to do without any difficulty to 3=Unable to do. Items are grouped into eight 
categories and category scores are adjusted for the need for assistance from others or the use 
of assistive devices. An overall disability index is calculated by averaging across the eight 
categories, with the overall index having a possible range of 0 to 3. (15, 16)
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The presence of depressive symptoms was assessed using the 20-item Center for 
Epidemiological Studies-Depression (CES-D) scale.(17) Participants rate the frequency with 
which they have experienced a particular symptom during the previous week. Responses 
were recorded on a 4-point scale ranging from 0=Rarely or none of the time to 3=Most or all 
of the time. Responses are summed across items to yield an overall score with a possible 
range of 0 to 60. The CES-D is widely-used to assess the presence of depressive symptoms 
in both community and patient samples.(18)
Participants rated how much of a problem unusual fatigue or tiredness had been in the past 
week using a visual analogue scale. Scale endpoints were labeled 0=no problem and 
100=major problem.(19, 20)
To assess comorbidities, participants were asked if they were currently experiencing, or had 
experienced in the past, any of 47 different conditions. This information was used to create 
an index based on the Charlson Comorbidity Index.(21) Ten types of conditions were 
included in this index: chronic lung problems (e.g., bronchitis, emphysema, asthma), stroke, 
myocardial infarction, stomach ulcer, Alzheimer's disease, rheumatoid arthritis, dialysis or 
kidney failure, paralysis of any kind, cancer, and diabetes. Each of the first six conditions 
was scored as “1” if it was currently present. A past history of either myocardial infarction 
or stroke was also scored as “1” each. Based on weights recommended by Charlson, the last 
four conditions were each scored as “2” if they were currently present.(21) The Charlson 
weights reflect the relative risk of 1-year mortality among people with a particular condition 
versus those without the condition. This variable had a possible range of 0 to 14.
Sociodemographic Characteristics—Sociodemographic characteristics included: age, 
gender (Male, Female), race (Caucasian, African-American), and education (High school or 
less, At least some college). This information was collected via self-report.
Statistical analyses—Descriptive statistics were used to describe the characteristics of 
study participants and the utilization of herbs/natural products and prescription/over-the-
counter medications. T-tests and Chi-square tests were used for demographic and clinical 
comparisons between the cohorts. Chi-square tests were used to evaluate differences in the 
utilization of herbal products across sample subgroups. To examine factors associated with 
exposure to potential medication-herb interactions, the sample was restricted to individuals 
who used at least one herb/natural product and at least one prescription/OTC medication. 
Unadjusted odds ratios were computed for each predictor variable (i.e., health insurance 
status, disability, depressive symptoms, fatigue, number of comorbidities, age, education, 
race, gender, number of herbs/natural products used, number of prescription/OTC 
medications used, and cohort membership). The predictor variables were selected to include: 
(1) demographic characteristics that have been associated with the use of herbs/natural 
products, (2) health status characteristics that may result in greater need for conventional 
medications or herbs/natural products, and (3) measures reflecting the number of herbs/
natural products and conventional medications used. To control for potential confounding, 
adjusted odds ratios were computed via a logistic regression model that controlled for all of 
the predictor variables. Due to missing data, the sample size for the full model was 419. 
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Model fit was assessed by the Hosmer-Lemeshow Goodness-of-Fit test.(22) All analyses 
were conducted using PC SAS version 9.1.(23)
Results
The full sample included 2523 individuals. Characteristics of study participants are shown in 
Table 1. Compared to participants in the original cohort (N=1571), participants in the second 
cohort (N=952): were younger (Means=59.5 years (SD=10.5) versus 65.8 years (SD=9.78), 
p < 0.0001); were less likely to have completed some college (24.3% versus 29.4%, p < 
0.006) or have health insurance (89.1% versus 94.4%, p < 0.0001); used more prescription 
medications (Means=4.2 (SD=3.1) versus 3.9 (SD=2.7), p < 0.02); used more OTC 
medications (Means=0.9 (SD=1.0) versus 0.79 (SD=0.9), p < 0.0001); were more likely to 
be African-American (41.3% versus 28.1%, p < 0.0001); and reported more disability 
(Means=0.60 (SD=0.66) versus 0.44 (SD=0.63), p < 0.0001), depressive symptoms 
(Means=8.8 (SD=10.0) versus 5.3 (SD=7.1), p < 0.0001), and fatigue (Means=19.4 
(SD=31.6) versus 15.8 (SD=27.3), p < 0.01). The two cohorts were similar in terms of 
gender, number of comorbidities, and number of herbs/natural products used.
Use of Herbs/Natural Products
As shown in Table 2, 19.3% (n=488) of the individuals in the full sample used at least one 
herb or natural product. Among these individuals, the number of products used ranged from 
1 to 20. However, most of these individuals (60.7%, n=296) used only one product. A little 
over 10% of herb/natural product users (n=51) used more than three products. The most 
commonly used herbs/natural products were: garlic (4.9%); glucosamine and/or chondroitin 
(3.2%); vinegar, honey, and cranberry juice or a combination of these (2.9%); and fish oils 
(2.4%). Subgroup comparisons indicated that herb/natural product use was more prevalent 
among women, Caucasians, and individuals with some college, compared to men, African-
Americans, and individuals with no more than a high school education, respectively.
Prevalence of Potential Medication – Herb/Natural Product Interactions
Of the 488 people who used one or more herbs/natural products, 443 (90.8%) also used at 
least one prescription/OTC medication, with all but 25 of these individuals using at least one 
prescription medication. The prescription/OTC medications most commonly used by herb/
natural product users are shown in Table 3. Relatively few people were using medications 
such as warfarin (n=6) and digoxin (n=12) that have a narrow therapeutic index.
Among the 443 people using at least one prescription/OTC medication and at least one herb/
natural product, 97 (21.9%) different individuals were using a combination of products 
associated with a potential interaction, representing 3.8% of the full sample. A total of 168 
potential interactions were identified. As shown in Table 4, 115 of the 168 potential 
interactions (68.5%) involved garlic and cytochrome P450 3A4 substrates (e.g., amlodipine, 
atorvastatin, simvastatin, verapamil). Although the severity of most of the 168 potential 
interactions was classified as “Moderate”, 27 (16.1%) were classified as “High” in severity.
Table 5 shows the results of bivariate and multivariate logistic regression analyses predicting 
exposure to a potential medication-herb/natural product interaction among individuals using 
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at least one prescription/OTC medication and at least one herb/natural product. The bivariate 
analyses indicate that the odds of exposure to a potential interaction increases with increases 
in: fatigue, number of comorbidities, number of herbs used, number of OTC medications 
used, and number of prescription medications used. In addition, individuals with health 
insurance were less likely to be exposed to a potential interaction than those without health 
insurance. Four of these variables remained statistically significant in the multivariate 
model: number of herbs used, number of OTC medications use, number of prescription 
medications used, and insurance status. In addition, disability was statistically significant in 
the multivariate model with the odds of exposure to a potential interaction lower among 
people with greater levels of disability. The Hosmer and Lemeshow goodness-of-fit test 
indicated that the final model provided a reasonable fit to the data (χ2 (8)=4.35, p=.82).
Discussion
Nearly 1 in 5 (19.3%) study participants used at least one herb/natural product, similar to 
that reported in recent national surveys.(2 3, 9) Consistent with past research, we too 
observed that women(3, 9, 49), Caucasians(2, 3, 9), and better educated individuals(3, 9, 49) 
were more likely to use these products.
Among individuals using at least one herb/natural product, almost all also used at least one 
prescription/OTC medication, and among these individuals, more than 1 in 5 (21.9%) were 
using a combination of products associated with a potential medication-herb interaction, 
representing 3.8% of the full sample. Although most of the identified potential interactions 
are considered of moderate severity, 27 are considered high in potential severity based on 
ratings included in the Natural Medicines Comprehensive Database.(11) These findings 
underscore the need to educate the public and health care providers about potential 
interactions between herbs/natural products and conventional medications. Further, our 
results highlight the need for physicians to ask patients about the use of herbs/natural 
products and to do so in a nonjudgmental way that encourages patients to provide accurate 
and complete information. Although we did not directly assess whether study participants 
had informed their health care provider about their use of herbs/natural products, previous 
research suggests that only about one in three people who use herbs/natural products report 
this information to their providers. (1, 8, 9) Thus, there is considerable need for 
improvement in this area.
Our findings also suggest that the risk of herb/natural product-conventional medication 
interactions is greater among individuals without health insurance and that the risk of 
interaction increases with the number of products used. Additional research is needed to 
confirm these findings in an independent sample. If confirmed, efforts directed at better 
understanding the nature of these relationships should be undertaken. For example, with 
respect to health insurance, research suggests that individuals without health insurance are 
more likely than others to forego needed medical care due to cost and to use herbs/natural 
products in an effort to self-manage their condition.(5) Thus, their use of herbs/natural 
products may be even less likely than others to be monitored by a health care provider. 
Future research should examine this possibility.
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This study has strengths in its biracial, population-based sample of men and women, its 
inclusion of an extensive array of herbs/natural products, and its detailed assessment of 
potential herb/natural product-conventional medication interactions. Several study 
limitations must also be noted. First, the sample was limited to Caucasian and African 
American residents of a single county in North Carolina. Therefore, the generalizability of 
study findings to other areas and racial and ethnic groups will need to be established by 
future research. Second, all data concerning herb/natural product and conventional 
medication use were obtained by self-report. Thus, any factors that might cause patients to 
provide incomplete or inaccurate information would jeopardize the validity of our findings. 
Third, we do not know that study participants were using the products implicated in the 
potential interactions concurrently, which would be necessary for an interaction to occur. 
However, the limited information that is available in the literature suggests that many people, 
including health care providers, have limited knowledge concerning the potential for 
interactions between conventional medications and herbs/natural products.(50-53) Without 
this knowledge, individuals who use both types of products are unlikely to be able to 
coordinate their use in a way that minimizes the potential for interaction. Finally, 
information concerning herb/natural product-conventional medication interactions continues 
to evolve. Evidence of potential interactions comes from many sources ranging from clinical 
trials and pharmacokinetic studies to in vitro research. In this study, we relied primarily on 
the Natural Medicines Comprehensive Database (online; professional version) which is 
updated daily as new information on herb/natural product-conventional medication 
interactions emerges. To restrict the number of interactions identified to those that are more 
likely to be clinically meaningful, we considered only interactions identified on the basis of 
clinical trials, pharmacokinetic studies, or case reports. Many more interactions would have 
been identified had we included interactions supported solely by in vitro or animal model 
research or theoretical interactions based on knowledge of mechanisms of action. 
Nonetheless, we recognize that interactions supported only by case-report data must also be 
regarded with caution. In addition, we were not able to determine if the potential interactions 
identified in this study were associated with deleterious patient health outcomes in our study 
population. This is a major limitation of the current study and represents an important area 
for future research.
In conclusion, our findings underscore the growing use of herbs/natural products in the 
United States. The concomitant use of prescription and OTC medications with herbs/natural 
products exposes patients to potential interactions among these products. In our sample, 
more than 1 in 5 (21.9%) people who were using both herbs/natural products and 
prescription/OTC medications were taking a combination of products associated with a 
potential interaction. This represented 3.8% of the full sample. Although some interactions 
may result in an immediate, life-threatening adverse event (e.g., bleeding episode), the 
effects of other interactions may be more insidious. For example, due to enzyme induction, 
the effectiveness of a chronic medication may be reduced with the initiation of an herbal 
remedy. If the interaction goes unrecognized, the dose of the medication may be increased or 
the medication may be changed unnecessarily, exposing the patient to greater risk. Given the 
growing use of both herbs/natural products and prescription/OTC medications, our findings 
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suggest an urgent need to better understand the effects that medication-herb/natural product 
interactions may have on clinical practice and patient health outcomes.
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Table 1
Characteristics of Full Sample and Subset of Individuals Who Used At Least One Herb/
Natural Product and At Least One Prescription/Over-the-Counter Medication
Characteristics Full Sample (N=2523)† Participants Who Used At Least One Herb/Natural Product 
and At Least One Prescription/Over-the- Counter Medication 
(N=443)‡
Mean Age, years (SD) 63.4 (10.5) 63.6 (9.9)
% Under 65 56.4 54.2
% Female 66.0 78.5
% African-American 33.0 24.6
% With Some College Education 27.5 33.3
% Health Insurance Coverage 92.4 93.6
Mean Disability Score (SD) 0.5 (0.6) 0.5 (0.7)
Mean Depression Score (SD) 6.6 (8.5) 7.5 (9.8)
Mean Fatigue Score (SD) 17.2 (29.0) 21.8 (31.3)
Mean # of Comorbidities (SD) 0.8 (1.1) 0.7 (1.1)
Mean # of Herbs/Natural Products Used (SD) 0.4 (1.2) 1.9 (1.9)
Mean # of Prescription Medications Used (SD) 3.6 (3.0) 4.0 (2.9)
Mean # of OTC Medications Used (SD) 0.7 (0.9) 0.8 (0.9)
†
Due to missing data, N's=2519 for age; 2510 for education, 2521 for gender and race; and 2399 for health insurance, disability, depression, 
fatigue, and comorbidities.
‡
Due to missing data, N's=442 for education and 419 for health insurance, disability, depression, fatigue, and comorbidities.
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Table 3
Therapeutic Classes of Medications Most Frequently Used By 433 Participants Also Using 
At Least One Herb/Natural Product
Therapeutic Class Number of Users Example of Medication in Class
Prescription Medications
 Beta-Adrenergic Blocking Agents 100 Metoprolol, Atenolol
 HMG-CoA Reductase Inhibitors 99 Atorvastatin, Simvastatin
 Estrogens 99 Conjugated estrogens
 Proton Pump Inhibitors* 89 Omeprazole, Lansoprazole
 Thiazide Diuretics 82 Hydrochlorothiazide
 Angiotensin-Converting Enzyme Inhibitors 81 Lisinopril, Enalapril
 Cycloxygenase-2 Inhibitors 65 Celecoxib
 Second Generation Antihistamines* 56 Fexofenadine
 Thyroid Agents 51 Levothyroxine
Over-The-Counter Medications
 Salicylates 150 Aspirin
 Other Nonsteroidal Anti-Inflammatory Agents 90 Ibuprofen, Naproxen
 Miscellaneous Analgesics and Antipyretics 60 Acetaminophen
*
Although some proton pump inhibitors and second generation antihistamines may now be purchased without a prescription, these agents were 
available only by prescription during most of the data collection period.
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Table 4
Potential Medication-Herb/Natural Product Interactions Observed Among 488 
Participants Using at Least One Herb/Natural Product and at Least One Prescription or 
Over-The-Counter Medication*





Class (# of Interactions)
Severity Comments
Garlic (124) 69 Cytochrome P450 3A4 
Substrates (114)†
Moderate Some garlic preparations appear to induce activity of 
CYP3A4 and reduce drug levels of substrates. 
However, results are inconsistent across studies. Until 
more is known, use caution when considering 
concomitant use of garlic and CYP3A4 substrates.
(24-25)
Dipyridamole (1) Moderate Compound found in garlic prevents platelet 
aggregation and might increase the risk of bleeding 
when combined with other antiplatelet agents.(26)
Ginkgo biloba (38) 17 Antidiabetes Drugs (7)‡ Moderate Use of ginkgo may result in a significant worsening 
of glucose tolerance.(27-28)
Omeprazole (3) Minor Use of ginkgo may decrease omeprazole levels. (29)
Ibuprofen (2) High There has been a case report of intracranial 
hemorrhage in a patient taking ibuprofen and ginkgo.
(30)
Lansoprazole (2) Moderate Use of ginkgo may decrease lansoprazole levels.(29)
Trazodone (2) High There has been a case report of coma in a patient 
taking trazodone and ginkgo. (31)
Clonazapam (1) High Use of ginkgo may lower seizure threshold among 
people taking anticonvulsants.(32-33)
St. Johns Wort (17) 10 Cytochrome P450 3A4 
Substrates (15)††
High St. John's Wort induces cytochrome P450 3A4 and 
reduces drug levels of substrates. It should be avoided 
among patients using CYP3A4 substrates.(34-37)
Cayenne Pepper (45) 10 Angiotensin-Converting 
Enzyme (ACE) Inhibitors 
(10)‡‡
Mild A case report suggests that topically applied cayenne 
pepper may contribute to ACE inhibitor-induced 
cough.(38)
Saw Palmetto (15) 4 Aspirin (4) High Concurrent use of saw palmetto and aspirin may 
increase bleeding risk and bleeding time.(39)
Ginseng (26) 2 Furosemide (2) Moderate There has been a case report of diuretic resistance in 
a patient taking furosemide plus a ginseng product 
containing other ingredients.(40)
Warfarin (1) Moderate Concurrent use of ginseng may decrease the 
effectiveness of warfarin therapy.(41)




1 Warfarin (1) High Increase INR following huge doses of glucosamine 
plus chondroitin.(43-45)
Melatonin (7) 1 Warfarin (1) High There have been case reports of minor bleeding and 
decreased prothrombin activity in people taking 
melatonin with warfarin.(46)
SAM-e (3) 1 Fluoxetine (1) High Concomitant use of these products may result in 
additive serotonergic effects and possible serotonin 
syndrome-like effects.(47-48)
*
Severity ratings and comments based on information available in Natural Medicines Comprehensive Database (online; professional version).11
†
The cytochrome P450 3A4 substrates most frequently involved in potential interactions with garlic were: amlodipine (n=16), atorvastatin (n=14), 
simvastatin (n=9), and verapamil (n=6).
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‡
The antidiabetes drugs involved in potential interactions with ginkgo biloba were: metformin (4), glyburide (2), and glipizide (1).
††
The cytochrome P450 3A4 substrates most frequently involved in potential interactions with St. Johns Wort were: fluticasone (n=2), 
medroxyprogesterone (n=2), and trazodone (n=2).
‡‡
The ACE Inhibitors involved in potential interactions with cayenne pepper were: lisinopril (6), benazepril (n=2), and enalapril (n=2).
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Table 5
Odds of Exposure to a Potential Medication-Herb/Natural Product Interaction Among 
Participants Using at Least One Herb/Natural Product and at Least One Prescription or 
Over-The-Counter Medication
Characteristics Odds Ratio (95% CI) p Adjusted Odds Ratio† (95% CI) p
Female 1.03 (0.58-1.82) .92 1.00 (0.53-1.92) .99
African-American 1.43 (0.85-2.40) .18 1.55 (0.86-2.78) .15
Age, years 1.02 (0.99-1.04) 0.14 1.03 (1.00-1.06) .06
Some College 1.09 (0.67-1.78) .73 1.08 (0.61-1.91) .80
Original Cohort 1.58 (0.96-2.61) 0.08 1.77 (0.99-3.16) .06
Health Insurance 0.31 (0.14-0.69) .004 0.34 (0.13-0.89) .03
Disability Score 1.22 (0.88-1.69) .24 0.61 (0.38-0.97) .04
Depression Score 1.02 (1.00-1.04) .10 1.01 (0.98-1.04) .44
Fatigue Score 1.01 (1.00-1.02) .004 1.00 (1.00-1.02) .11
# of Comorbidities 1.44 (1.19-1.74) .0002 1.27 (0.99-1.61) .06
# of Herbs Used 1.31 (1.13-1.51) .0002 1.29 (1.10-1.51) .001
# of OTC Medications Used 1.32 (1.04-1.67) .03 1.44 (1.09-1.91) .01
# of Prescription Medications Used 1.14 (1.06-1.24) .0005 1.13 (1.02-1.26) 0.02
†
Due to missing data, N=419 in the logistic regression model.
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